This year in the United States, nearly 221,000 men will be told they have prostate cancer. About 30 percent of those cancers will have already spread outside the prostate. Now, doctors have discovered a way to keep it from spreading even further.
Robert Miller is a force in front of his congregation. Preaching is his life's work. His life's battle started 11 years ago when he was diagnosed with prostate cancer.
"All I heard was the word cancer and I'm thinking cancer, death, cancer, death," Miller tells Ivanhoe.
PSA levels, the markers for prostate cancer, are considered high at four. At diagnosis, Miller's levels were nearly 80. His prostate was removed, but the cancer stayed behind. He soon found oncologist Michael Carducci, M.D.
When prostate cancer spreads, it first goes to the bones. Dr. Carducci is studying the drug atrasentan to keep the cancer from getting there.
It does that by targeting endothelin -- a protein overproduced in men with prostate cancer that has spread.
Dr. Carducci says, "We get to the lock before endothelin does and therefore, the cancer cells never see this growth factor, this protein that really stimulates further growth."